| Assay ID | Title | Year | Journal | Article |
|---|
| AID144660 | Inhibition of NCI cell line proliferation | 2000 | Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. |
| AID1437533 | Inhibition of recombinant human full-length C-terminal His6-tagged Cdk9/human full-length Cyclin T expressed in baculovirus infected Sf21 insect cells relative to untreated control | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. |
| AID320945 | Inhibition of CDK2/Cyclin A | 2008 | Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
| Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. |
| AID269196 | Inhibition of CDK2 | 2006 | Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
| Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations. |
| AID1437523 | Inhibition of Cdk4/Cyclin D (unknown origin) relative to untreated control | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. |
| AID55539 | Inhibition of Cyclin-dependent kinase 1 (CDK1) at 12.5 uM ATP | 2003 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
| Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. |
| AID1549303 | Inhibition of human CDK2/Cyclin A3 (171 to 432 residues) (unknown origin) | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
| Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID551120 | Inhibition of ASK1 assessed as phosphorylated fluorescent peptide by mobility shift assay | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
| Identification of novel ASK1 inhibitors using virtual screening. |
| AID551121 | Inhibition of ASK1 assessed as phosphorylated fluorescent peptide at 10 uM by mobility shift assay | 2011 | Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
| Identification of novel ASK1 inhibitors using virtual screening. |
| AID739929 | Cytotoxicity against african green monkey Vero cells by non-radioactive cell proliferation assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
| 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID1437513 | Inhibition of human CDK5 (unknown origin) | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. |
| AID739930 | Antimycobacterial activity against Mycobacterium avium Nj211 assessed as growth inhibition by Alamar blue microdilution broth assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
| 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID103760 | Inhibition of MCF-7 human breast carcinoma cell proliferation | 2002 | Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
| Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. |
| AID53535 | Inhibition of human Cyclin-dependent kinase 2-cyclin A | 2002 | Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
| Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. |
| AID1437518 | Inhibition of recombinant human CDK1/Cyclin B expressed in baculovirus infected Sf9 cells using PKTPKKAKKL-NH2 as substrate | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. |
| AID53499 | Inhibition of Cyclin-dependent kinase 2 enzyme from starfish oocytes | 2000 | Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. |
| AID740172 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition by radiometric BACTEC assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
| 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID53195 | Inhibitory activity against cyclin-dependent kinase 1-cyclin B. | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. |
| AID53674 | Inhibition of human Cyclin-dependent kinase 2-cyclin A | 2002 | Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
| Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. |
| AID31157 | Concentration required to reduce AGT activity to 50% of control rate in intact HT-29 human colorectal carcinoma cells; ND denotes no data | 2000 | Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
| Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine. |
| AID53352 | Inhibition of starfish oocyte (Marthasteria glacialis) Cyclin-dependent kinase 1-cyclin B1 | 2002 | Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
| Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. |
| AID53364 | Inhibition of Cyclin-dependent kinase 2 (CDK2) at 12.5 uM ATP | 2003 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
| Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. |
| AID1549262 | Inhibition of starfish oocyte CDK1/cyclin B1 | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
| Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID31158 | Percent AGT inactivation in HT-29 cell extract at 1 mM | 2000 | Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
| Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine. |
| AID320943 | Inhibition of CDK1/Cyclin B | 2008 | Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
| Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model. |
| AID371507 | Antiproliferative activity against human MCF7 cells after 3 days by SRB assay | 2008 | European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
| Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines. |
| AID740174 | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/ml by radiometric BACTEC assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
| 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID1065929 | Inhibition of CDK2/cyclin A3 (unknown origin) | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode. |
| AID53169 | Inhibition of Cyclin-dependent kinase 1 enzyme from starfish oocytes | 2000 | Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. |
| AID53531 | Inhibition of cyclin-dependent kinase 2-CyclinA3 | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. |
| AID1437509 | Inhibition of CDK2 (unknown origin) | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. |
| AID740173 | Antimycobacterial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 assessed as growth inhibition by Alamar blue microdilution broth assay | 2013 | Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
| 6-Oxo and 6-thio purine analogs as antimycobacterial agents. |
| AID31151 | concentration required to reduce AGT activity to 50% of control rate in HT-29 cell extract. | 2000 | Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
| Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine. |
| AID1549290 | Inhibition of CDK4 (unknown origin) | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
| Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. |
| AID1065925 | Inhibition of CDK1/Cyclin B (unknown origin) | 2014 | Journal of medicinal chemistry, Jan-09, Volume: 57, Issue:1
| 8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode. |
| AID1437524 | Inhibition of recombinant human full-length C-terminal His6-tagged Cdk7/recombinant human full-length Cyclin H expressed in baculovirus infected Sf21 insect cells relative to untreated control | 2017 | Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
| Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines. |
| AID53358 | Inhibition of starfish oocyte (Marthasteria glacialis) Cyclin-dependent kinase 1-cyclin B1 | 2002 | Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
| Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7
| Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1795788 | Kinase Inhibition Assay from Article 10.1021/jm990628o: \\Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.\\ | 2000 | Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. |
| AID1795782 | Kinase Inhibition Assay from Article 10.1021/jm0311442: \\N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.\\ | 2004 | Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
| N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. |
| AID1795776 | Kinase Inhibition Assay from Article 10.1021/jm020056z: \\Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.\\ | 2002 | Journal of medicinal chemistry, Aug-01, Volume: 45, Issue:16
| Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2000 | Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2000 | Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |